0001858685
false
--12-31
0001858685
2023-06-28
2023-06-28
0001858685
BFRI:CommonStockParValue0.001PerShareMember
2023-06-28
2023-06-28
0001858685
BFRI:PreferredStockPurchaseRightsMember
2023-06-28
2023-06-28
0001858685
BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember
2023-06-28
2023-06-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 28,
2023
Biofrontera
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40943 |
|
47-3765675 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
120
Presidential Way, Suite 330
Woburn,
Massachusetts |
|
01801 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781) 245-1325
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on
which registered |
Common stock, par value
$0.001 per share |
|
BFRI |
|
The Nasdaq Stock Market
LLC |
Preferred Stock Purchase
Rights |
|
|
|
The Nasdaq Stock Market
LLC |
Warrants, each warrant
exercisable for one share of common stock, each at an exercise price of $5.00 per share |
|
BFRIW |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.03. Material Modification to Rights of Security
Holders.
On June 28, 2023, Biofrontera
Inc., (“the Company”), filed a Certificate of Amendment to its Amended and Restated
Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (i) effect a 1-for-20
reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.001 par value (the “Common
Stock”), and (ii) effect a related proportional reduction in the number of the Company’s authorized shares of Common
Stock from 300,000,000 to 15,000,000 (the “Authorized Share Reduction”).
As previously disclosed, at
a special meeting held on May 22, 20223, the Company’s stockholders approved the Reverse Stock Split with a ratio within a range
of between 1-for-5 and 1-for-25, with the exact ratio to be set at the discretion of the Company’s Board of Directors, and the
Authorized Share Reduction, each of which the Board also approved. On June 26, 2023, the Board of Directors approved a ratio of 1-for-20
for the Reverse Stock Split.
Pursuant to the Amendment,
the Reverse Stock Split and Authorized Share Reduction will be effective at 11:59 p.m. on July 3, 2023 (the “Split Effective Time”),
and the Common Stock will be begin trading on the Nasdaq Capital Market on a post-split basis when the market opens on July 5, 2023.
The Company’s post-split Common Stock has a new CUSIP number, 09077D 209, but the par value and other terms of the Common Stock
were not affected. The trading symbol of the Company’s Common Stock will continue to be “BFRI.”
Following the Split Effective
Time, every 20 shares of Biofrontera Inc. common stock issued and outstanding will be automatically combined and reclassified
into one share of common stock. Outstanding equity-based awards, warrants and other equity rights will be proportionately
adjusted pursuant to their terms and the number of shares authorized and reserved for issuance upon vesting of restricted stock units
or exercise of stock options and warrants will be reduced proportionately. No fractional shares will be issued as a result of the
reverse stock split. Stockholders who would otherwise hold a fractional share as a result of the Reverse Stock Split will
receive an additional share of common stock.
The
Company’s publicly traded warrants will continue to be traded on the Nasdaq Capital Market under the symbol “BFRIW”
and the CUSIP number for the warrants will remain unchanged. However, under the terms of the applicable warrant agreement, the number
of shares of Common Stock issuable on exercise of each warrant will be proportionately decreased. Specifically, following effectiveness
of the Reverse Stock Split, every 20 shares of Common Stock that may be purchased pursuant to the exercise of public warrants now represents
one share of Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under
the symbol “BFRIW”, every 20 warrants will be exercisable for one share of Common Stock at an exercise price of $100.00 per
share of Common Stock.
The Reverse Stock Split affected
all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity (other than as
a result of the rounding up of fractional shares). Shortly following the Split Effective Time, stockholders of record will be receiving
information from Computershare Trust Company, N.A., the Company’s transfer agent, regarding their stock ownership following the
Reverse Stock Split. Stockholders who hold their shares in brokerage accounts or in “street name” are not required to take
any action in connection with the Reverse Stock Split. Their accounts will be automatically adjusted to reflect the number of shares
owned.
The foregoing description
of the Amendment and the Reverse Stock Split set forth above does not purport to be complete and is qualified in its entirety by reference
to the Amendment. A copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
Item 5.03. Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.
The
disclosures set forth in Item 3.03 of this Current Report on Form 8-K are incorporated into this Item 5.03 by reference.
Item 7.01 Regulation FD Disclosure.
On July 3, 2023, the Company
issued a press release announcing the Reverse Stock Split ratio, a copy of which is attached here as Exhibit 99.1 to this Current
Report on Form 8-K.
The
information in Item 7.01 of this Current Report is being furnished and shall not be deemed
“filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended.
Item
9.01 Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
July
3, 2023
(Date) |
Biofrontera
Inc.
(Registrant) |
|
|
|
/s/
E. Fred Leffler III |
|
E. Fred Leffler III |
|
Chief Financial Officer |
Exhibit
3.1
CERTIFICATE
OF AMENDMENT
TO
THE
AMENDED
AND RESTATED CERTIFICATE OF INCORPORATION OF
OF
BIOFRONTERA
INC.
Biofrontera
Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation
Law of the State of Delaware (the “DGCL”), does hereby certify:
FIRST.
The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended, such amendment to become effective at the
Split Effective Time (as defined below), by changing the Article FOURTH, so that, as amended, the first paragraph of said Article FOURTH
shall be amended and restated as follows:
The
total number of shares of capital stock that the Corporation has the authority to issue shall be (i) 15,000,000 shares of common stock,
par value $0.001 per share (“Common Stock”) and (ii) 20,000,000 shares of preferred stock, par value $0.001 per share
(“Preferred Stock”).
SECOND.
At 11:59 p.m. on July 3, 2023 (the “Split Effective Time”), every twenty (20) issued and outstanding shares
of the Corporation’s common stock, par value $.001 per share, as of the date and time immediately preceding the Split Effective
Time (the “Old Shares”), shall automatically be reclassified as and converted into one (1) validly issued,
fully paid and non-assessable share of common stock of the Corporation (the “New Shares”) without any further
action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the “Reverse
Stock Split”). Further, every right, option and warrant to acquire Old Shares outstanding immediately prior to the Split
Effective Time shall, as of the Split Effective Time and without any further action, automatically be reclassified into the right to
acquire one (1) New Share for every twenty (20) Old Shares, but otherwise upon the terms of such right, option or warrant (except that
the exercise or purchase price of such right, option or warrant shall be proportionately adjusted). No fractional shares shall be issued
in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of common stock
shall receive that number of New Shares based on the conversion ratio of their shares of Old Shares to New Shares set forth above, rounded
up to the next whole share of common stock.
THIRD.
That a resolution was duly adopted by unanimous written consent of the directors of the Corporation, pursuant to Section 242 of the DGCL,
setting forth the above mentioned amendment to the Amended and Restated Certificate of Incorporation and declaring said amendment to
be advisable.
FOURTH.
That this amendment was duly authorized by the holders of a majority of the voting stock of the Corporation entitled to vote at a duly
authorized meeting of the stockholders of the Corporation held on May 22, 2023. Said amendment was duly adopted in accordance with the
provisions of the DGCL.
IN
WITNESS WHEREOF, this Certificate of Amendment of the Amended and Restated Certificate of Incorporation has been signed by the Chief
Financial Officer of the Corporation this 28th day of June, 2023.
|
BIOFRONTERA INC. |
|
|
|
|
By: |
/s/
E. Fred Leffler III |
|
Name: |
E.
Fred Leffler, III |
|
Title: |
Chief Financial
Officer |
Exhibit
99.1
Biofrontera
Inc. Announces 1-for-20 Reverse Stock Split
WOBURN,
Mass. (July 3, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical
company specializing in the commercialization of dermatologic products, announces that it will effect a reverse stock split of
its outstanding shares of common stock at a ratio of 1-for-20 that will become effective after the close of trading at 11:59
p.m. today. Biofrontera Inc. common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on
Wednesday, July 5, 2023 under the existing symbol, BFRI, and under a new CUSIP number, 09077D 209.
Upon
effectiveness of the reverse stock split, every 20 shares of Biofrontera Inc. common stock issued and outstanding will be automatically
combined into one share of common stock. Outstanding equity-based awards and other equity rights will be proportionately adjusted. No fractional
shares will be issued as a result of the reverse stock split. Stockholders otherwise entitled to receive a fractional share as a result
of the reverse stock split will automatically receive an additional fraction of a share of common stock to round up to the next whole
share.
The
Company’s publicly traded warrants will continue to be traded on Nasdaq under the symbol “BFRIW” and the CUSIP number
for the warrants will remain unchanged. However, under the terms of the applicable warrant agreement, the number of shares of common
stock issuable on exercise of each warrant will be proportionately decreased. Specifically, on a split-adjusted basis, every 20 shares
of common stock that may be purchased pursuant to the exercise of public warrants now represents one share of common stock that may be
purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under the symbol “BFRIW”, every
20 warrants will be exercisable for one share of common stock at an exercise price of $100.00 per share.
This
reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement for
continued listing.
“This
reverse stock split, which was approved by our shareholders and authorized by our Board of Directors, should allow Biofrontera
to regain compliance with Nasdaq’s continued-listing requirements. Additionally, we believe the post-split stock price may make
an investment in Biofrontera more attractive to a broader group of investors,” commented Hermann Luebbert, Chief Executive Officer
and Chairman of Biofrontera Inc.
The
reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s
equity (other than as a result of the rounding up of fractional shares). Stockholders of record will be receiving information from Computershare
Trust Company, N.A., the Company’s transfer agent, regarding their stock ownership following the reverse stock split. Stockholders
who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect
the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connection
with the reverse stock split.
Additional
information concerning the reverse stock split can be found in Biofrontera Inc.’s definitive proxy statement filed with
the U.S. Securities and Exchange Commission on April 21, 2023.
About
Biofrontera Inc.
Biofrontera
Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with
a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com
and follow Biofrontera on LinkedIn and Twitter.
Forward-Looking
Statements
Certain
statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to
for the implementation of the reverse stock split, the impact of the reverse stock split on the Company and its stock
price, the likelihood of regaining compliance with Nasdaq’s listing requirements and the investment appeal of the Company. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless,
actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of
any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s
licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability;
whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed
products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures
using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability
and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination
with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing
or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether
the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s
expectations; the Company’s ability to comply with public company requirements; the Company’s ability to regain compliance
with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources
and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained
on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only
as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company
does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this
press release except as required by law.
Contact:
LHA
Investor Relations
Tirth
T. Patel
212-201-6614
tpatel@lhai.com
#
# #
v3.23.2
Cover
|
Jun. 28, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jun. 28, 2023
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-40943
|
Entity Registrant Name |
Biofrontera
Inc.
|
Entity Central Index Key |
0001858685
|
Entity Tax Identification Number |
47-3765675
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
120
Presidential Way
|
Entity Address, Address Line Two |
Suite 330
|
Entity Address, City or Town |
Woburn
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01801
|
City Area Code |
(781)
|
Local Phone Number |
245-1325
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
Common stock, par value $0.001 per share |
|
Title of 12(b) Security |
Common stock, par value
$0.001 per share
|
Trading Symbol |
BFRI
|
Security Exchange Name |
NASDAQ
|
Preferred Stock Purchase Rights |
|
Title of 12(b) Security |
Preferred Stock Purchase
Rights
|
Security Exchange Name |
NASDAQ
|
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share |
|
Title of 12(b) Security |
Warrants, each warrant
exercisable for one share of common stock, each at an exercise price of $5.00 per share
|
Trading Symbol |
BFRIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_CommonStockParValue0.001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_PreferredStockPurchaseRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024